{"id":10516,"date":"2026-04-02T10:02:29","date_gmt":"2026-04-02T10:02:29","guid":{"rendered":"https:\/\/jurmed.ro\/pacienti\/?p=10516"},"modified":"2026-04-02T10:02:29","modified_gmt":"2026-04-02T10:02:29","slug":"progres-major-in-managementul-cancerului-de-prostata-darolutamida-devine-disponibila-pacientilor-din-romania-incepand-cu-2026","status":"publish","type":"post","link":"https:\/\/jurmed.ro\/pacienti\/progres-major-in-managementul-cancerului-de-prostata-darolutamida-devine-disponibila-pacientilor-din-romania-incepand-cu-2026\/","title":{"rendered":"Progres major \u00een managementul cancerului de prostat\u0103: Darolutamida devine disponibil\u0103 pacien\u021bilor din Rom\u00e2nia \u00eencep\u00e2nd cu 2026"},"content":{"rendered":"<p>&nbsp;<\/p>\n<p>Pacien\u021bii din Rom\u00e2nia care sufer\u0103 de cancer de prostat\u0103 beneficiaz\u0103, \u00eencep\u00e2nd cu acest an, de o nou\u0103 op\u021biune terapeutic\u0103 esen\u021bial\u0103. Bayer anun\u021b\u0103 disponibilitatea darolutamidei pe pia\u021ba local\u0103, un inhibitor oral al receptorilor androgenici (ARi), care marcheaz\u0103 un progres semnificativ \u00een controlul bolii \u0219i alinierea sistemului medical rom\u00e2nesc la standardele interna\u021bionale de \u00eengrijire.<\/p>\n<p>Noua terapie se refer\u0103 la dou\u0103 indica\u021bii clinice, oferind solu\u021bii concrete pentru categorii de pacien\u021bi cu nevoi medicale complexe: l Cancerul de prostat\u0103 non-metastatic rezistent la castrare (nmCRPC), \u00een special pentru pacien\u021bii cu risc crescut de a dezvolta metastaze; l Cancerul de prostat\u0103 metastatic sensibil la terapia hormonal\u0103 (mHSPC). Importan\u021ba acestei noi op\u021biuni terapeutice este confirmat\u0103 de statisticile actuale: cancerul de prostat\u0103 este al doilea cel mai frecvent tip de cancer la b\u0103rba\u021bi \u0219i se afl\u0103 pe locul cinci ca principal\u0103 cauz\u0103 de deces prin cancer la nivel mondial1. Conform datelor GLOBOCAN 2022, \u00een Rom\u00e2nia au fost \u00eenregistrate 10.442 de cazuri noi de cancer de prostat\u0103, ceea ce reprezint\u0103 18,2% din totalul cazurilor de cancer diagnosticate la b\u0103rba\u021bi2. Datele statistice arat\u0103 c\u0103 aproximativ unul din trei pacien\u021bi diagnostica\u021bi cu mHSPC (cancer de prostat\u0103 metastatic sensibil la terapia hormonal\u0103) supravie\u021buie\u0219te cel pu\u021bin cinci ani, \u00eens\u0103 majoritatea acestora evolueaz\u0103 spre forma rezistent\u0103 la castrare (CRPC). Chiar dac\u0103 majoritatea b\u0103rba\u021bilor sunt diagnostica\u021bi ini\u021bial cu o form\u0103 localizat\u01033, 4, abordabil\u0103 prin chirurgie curativ\u0103 sau radioterapie, riscul de recidiv\u0103 \u0219i metastaz\u0103 r\u0103m\u00e2ne semnificativ. \u00cen aceste stadii, terapia de deprivare androgenic\u0103 (ADT) constituie pilonul principal de tratament, al\u0103turi de op\u021biuni precum inhibitorii c\u0103ii receptorilor androgenici sau chimioterapia cu docetaxel. Cu toate acestea, progresia c\u0103tre stadii metastatice avansate r\u0103m\u00e2ne o provocare major\u0103, fiind asociat\u0103 cu o morbiditate ridicat\u0103 \u0219i o supravie\u021buire limitat\u0103.<br \/>\n\u00cen acest context, detectarea timpurie a cancerului de prostat\u0103 r\u0103m\u00e2ne condi\u021bia esen\u021bial\u0103 pentru cre\u0219terea ratelor de supravie\u021buire. Implementarea screeningului regulat \u0219i o mai bun\u0103 cunoa\u0219tere a factorilor de risc sunt pilonii care permit identificarea bolii \u00een stadii curabile, \u00eenainte ca aceasta s\u0103 progreseze c\u0103tre forme severe, dificil de controlat.<br \/>\n\u201cUtilizarea triplei terapii (Darolutamid\u0103 + Docetaxel + ADT) reprezint\u0103 actualul \u201estandard detratament\u201d pentru pacien\u021bii cu cancer de prostat\u0103 metastatic sensibil la castrare (mHSPC) cu volum tumoral mare (high-volume). Aceast\u0103 abordare transform\u0103 managementul bolii dintr-o succesiune de tratamente \u00eentr-un atac frontal, precoce \u0219i agresiv. Tripla terapie nu adaug\u0103 doar un medicament \u00een plus, ci schimb\u0103 traiectoria bolii. Pentru un pacient cu volum mare, neutilizarea triplei terapii (dac\u0103 pacientul este eligibil pentru Docetaxel) \u00eenseamn\u0103 a-i oferi o \u0219ans\u0103 mai mic\u0103 la supravie\u021buire pe termen lung.\u201d, a declarat dr. Radu Serescu, medic oncolog, Amethyst Bucure\u015fti.<br \/>\n\u201ePrezentarea la medic pentru controale periodice, diagnosticarea afec\u021biunii \u00een stadii incipiente, \u00eempreun\u0103 cu accesul echitabil la solu\u021bii inovatoare, \u00een acela\u0219i timp cu al\u0163i cet\u0103\u0163eni europeni, sunt esen\u0163iale pentru \u00eembun\u0103t\u0103\u021birea calit\u0103\u021bii vie\u0163ii \u015fi a prognosticului pacien\u021bilor oncologici. Prin intermediul cercet\u0103rii continue \u0219i al dezvolt\u0103rii \u0219tiin\u021bifice, Bayer \u00ee\u0219i men\u021bine angajamentul de a face progrese \u00een domeniul tratamentelor oncologice, \u015fi pune un accent deosebit pe prelungirea \u0219i \u00eembun\u0103t\u0103\u021birea vie\u021bii pacien\u021bilor care se confrunt\u0103 cu cancer de prostat\u0103.\u201d, a declarat C\u0103t\u0103lina Urse, Country Manager Pharmaceuticals, Bayer Rom\u00e2nia \u0219i Republica Moldova Bayer se dedic\u0103 identific\u0103rii \u0219i abord\u0103rii nevoilor specifice ale persoanelor diagnosticate cu cancer de prostat\u0103, oferind terapii care le permit s\u0103 navigheze prin fiecare etap\u0103 a bolii cu speran\u021b\u0103 \u0219i s\u0103 \u00ee\u0219i continue activit\u0103\u021bile zilnice pentru o via\u021b\u0103 mai lung\u0103 \u0219i mai bun\u0103. Un pilon central al acestui portofoliu de inova\u021bie este darolutamida, un inhibitor oral al receptorilor androgenici (ARi) cu o structur\u0103 chimic\u0103 distinct\u0103, care se leag\u0103 cu afinitate ridicat\u0103 de receptorul androgenic \u0219i ac\u021bioneaz\u0103 ca un antagonist puternic, inhib\u00e2nd func\u021bia \u0219i proliferarea celulelor cancerului de prostat\u0103. Studiile preclinice sugereaz\u0103 un poten\u021bial redus de traversare a barierei hemato-encefalice. De asemenea, produsul este aprobat \u00een peste 70 de \u021b\u0103ri la nivel global.<br \/>\n1. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians. HYPERLINK &#8222;https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/epdf\/10.3322\/caac.21660&#8243;Link.<br \/>\n2. GLOBOCAN Romania Fact Sheet 2022: &#8222;https:\/\/gco.iarc.who.int\/media\/globocan\/factsheets\/populations\/642-romania-fact-sheet.pdf&#8221;Link.<br \/>\n3. Ng, K., Smith, S., Shamash, J. Metastatic Hormone-Sensitive Prostate Cancer (mHSPC): Advances and Treatment Strategies in the First-Line Setting. Oncol Ther 8, 209\u2013230 (2020). &#8222;https:\/\/doi.org\/10.1007\/s40487-020-00119-z&#8221;Link.<br \/>\n4. Hahn AW, Higano CS, Taplin ME, Ryan CJ, Agarwal N. Metastatic Castration-Sensitive Prostate Cancer: Optimizing Patient Selection and Treatment. Am Soc Clin Oncol Educ Book. 2018 May 23;38:363-371. &#8222;https:\/\/doi.org\/10.1200\/edbk_200967&#8243;Link.<\/p>\n<p style=\"text-align: justify;\">\n","protected":false},"excerpt":{"rendered":"<p>&nbsp; Pacien\u021bii din Rom\u00e2nia care sufer\u0103 de cancer de prostat\u0103 beneficiaz\u0103, \u00eencep\u00e2nd cu acest an, de o nou\u0103 op\u021biune terapeutic\u0103 esen\u021bial\u0103. Bayer anun\u021b\u0103 disponibilitatea darolutamidei pe pia\u021ba local\u0103, un inhibitor [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":10517,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_exactmetrics_skip_tracking":false,"_exactmetrics_sitenote_active":false,"_exactmetrics_sitenote_note":"","_exactmetrics_sitenote_category":0,"footnotes":""},"categories":[67],"tags":[102,1541],"class_list":["post-10516","post","type-post","status-publish","format-standard","has-post-thumbnail","category-articole","tag-oncologie","tag-progres-major-in-managementul-cancerului-de-prostata-darolutamida-devine-disponibila-pacientilor-din-romania-incepand-cu-20"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.0 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Progres major \u00een managementul cancerului de prostat\u0103: Darolutamida devine disponibil\u0103 pacien\u021bilor din Rom\u00e2nia \u00eencep\u00e2nd cu 2026 - Jurmed - Pacienti<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/jurmed.ro\/pacienti\/progres-major-in-managementul-cancerului-de-prostata-darolutamida-devine-disponibila-pacientilor-din-romania-incepand-cu-2026\/\" \/>\n<meta property=\"og:locale\" content=\"ro_RO\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Progres major \u00een managementul cancerului de prostat\u0103: Darolutamida devine disponibil\u0103 pacien\u021bilor din Rom\u00e2nia \u00eencep\u00e2nd cu 2026 - Jurmed - Pacienti\" \/>\n<meta property=\"og:description\" content=\"&nbsp; Pacien\u021bii din Rom\u00e2nia care sufer\u0103 de cancer de prostat\u0103 beneficiaz\u0103, \u00eencep\u00e2nd cu acest an, de o nou\u0103 op\u021biune terapeutic\u0103 esen\u021bial\u0103. Bayer anun\u021b\u0103 disponibilitatea darolutamidei pe pia\u021ba local\u0103, un inhibitor [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/jurmed.ro\/pacienti\/progres-major-in-managementul-cancerului-de-prostata-darolutamida-devine-disponibila-pacientilor-din-romania-incepand-cu-2026\/\" \/>\n<meta property=\"og:site_name\" content=\"Jurmed - Pacienti\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-02T10:02:29+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/jurmed.ro\/pacienti\/wp-content\/uploads\/sites\/3\/2026\/04\/Medinst_Logo___1_300_162_r@2x.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"600\" \/>\n\t<meta property=\"og:image:height\" content=\"324\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Gabriel\" \/>\n<meta name=\"twitter:label1\" content=\"Scris de\" \/>\n\t<meta name=\"twitter:data1\" content=\"Gabriel\" \/>\n\t<meta name=\"twitter:label2\" content=\"Timp estimat pentru citire\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/jurmed.ro\/pacienti\/progres-major-in-managementul-cancerului-de-prostata-darolutamida-devine-disponibila-pacientilor-din-romania-incepand-cu-2026\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/jurmed.ro\/pacienti\/progres-major-in-managementul-cancerului-de-prostata-darolutamida-devine-disponibila-pacientilor-din-romania-incepand-cu-2026\/\"},\"author\":{\"name\":\"Gabriel\",\"@id\":\"https:\/\/jurmed.ro\/pacienti\/#\/schema\/person\/33a8cfa97687970b1e60b21cfefad2fa\"},\"headline\":\"Progres major \u00een managementul cancerului de prostat\u0103: Darolutamida devine disponibil\u0103 pacien\u021bilor din Rom\u00e2nia \u00eencep\u00e2nd cu 2026\",\"datePublished\":\"2026-04-02T10:02:29+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/jurmed.ro\/pacienti\/progres-major-in-managementul-cancerului-de-prostata-darolutamida-devine-disponibila-pacientilor-din-romania-incepand-cu-2026\/\"},\"wordCount\":813,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/jurmed.ro\/pacienti\/progres-major-in-managementul-cancerului-de-prostata-darolutamida-devine-disponibila-pacientilor-din-romania-incepand-cu-2026\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/jurmed.ro\/pacienti\/wp-content\/uploads\/sites\/3\/2026\/04\/Medinst_Logo___1_300_162_r@2x.jpg\",\"keywords\":[\"oncologie\",\"Progres major \u00een managementul cancerului de prostat\u0103: Darolutamida devine disponibil\u0103 pacien\u021bilor din Rom\u00e2nia \u00eencep\u00e2nd cu 20\"],\"articleSection\":[\"Articole\"],\"inLanguage\":\"ro-RO\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/jurmed.ro\/pacienti\/progres-major-in-managementul-cancerului-de-prostata-darolutamida-devine-disponibila-pacientilor-din-romania-incepand-cu-2026\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/jurmed.ro\/pacienti\/progres-major-in-managementul-cancerului-de-prostata-darolutamida-devine-disponibila-pacientilor-din-romania-incepand-cu-2026\/\",\"url\":\"https:\/\/jurmed.ro\/pacienti\/progres-major-in-managementul-cancerului-de-prostata-darolutamida-devine-disponibila-pacientilor-din-romania-incepand-cu-2026\/\",\"name\":\"Progres major \u00een managementul cancerului de prostat\u0103: Darolutamida devine disponibil\u0103 pacien\u021bilor din Rom\u00e2nia \u00eencep\u00e2nd cu 2026 - Jurmed - Pacienti\",\"isPartOf\":{\"@id\":\"https:\/\/jurmed.ro\/pacienti\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/jurmed.ro\/pacienti\/progres-major-in-managementul-cancerului-de-prostata-darolutamida-devine-disponibila-pacientilor-din-romania-incepand-cu-2026\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/jurmed.ro\/pacienti\/progres-major-in-managementul-cancerului-de-prostata-darolutamida-devine-disponibila-pacientilor-din-romania-incepand-cu-2026\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/jurmed.ro\/pacienti\/wp-content\/uploads\/sites\/3\/2026\/04\/Medinst_Logo___1_300_162_r@2x.jpg\",\"datePublished\":\"2026-04-02T10:02:29+00:00\",\"author\":{\"@id\":\"https:\/\/jurmed.ro\/pacienti\/#\/schema\/person\/33a8cfa97687970b1e60b21cfefad2fa\"},\"breadcrumb\":{\"@id\":\"https:\/\/jurmed.ro\/pacienti\/progres-major-in-managementul-cancerului-de-prostata-darolutamida-devine-disponibila-pacientilor-din-romania-incepand-cu-2026\/#breadcrumb\"},\"inLanguage\":\"ro-RO\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/jurmed.ro\/pacienti\/progres-major-in-managementul-cancerului-de-prostata-darolutamida-devine-disponibila-pacientilor-din-romania-incepand-cu-2026\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"ro-RO\",\"@id\":\"https:\/\/jurmed.ro\/pacienti\/progres-major-in-managementul-cancerului-de-prostata-darolutamida-devine-disponibila-pacientilor-din-romania-incepand-cu-2026\/#primaryimage\",\"url\":\"https:\/\/jurmed.ro\/pacienti\/wp-content\/uploads\/sites\/3\/2026\/04\/Medinst_Logo___1_300_162_r@2x.jpg\",\"contentUrl\":\"https:\/\/jurmed.ro\/pacienti\/wp-content\/uploads\/sites\/3\/2026\/04\/Medinst_Logo___1_300_162_r@2x.jpg\",\"width\":600,\"height\":324},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/jurmed.ro\/pacienti\/progres-major-in-managementul-cancerului-de-prostata-darolutamida-devine-disponibila-pacientilor-din-romania-incepand-cu-2026\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/jurmed.ro\/pacienti\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Progres major \u00een managementul cancerului de prostat\u0103: Darolutamida devine disponibil\u0103 pacien\u021bilor din Rom\u00e2nia \u00eencep\u00e2nd cu 2026\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/jurmed.ro\/pacienti\/#website\",\"url\":\"https:\/\/jurmed.ro\/pacienti\/\",\"name\":\"Jurmed - Pacienti\",\"description\":\"JURMED \u2013 Jurnal de Sanatate este o publicatie lunara de informare si preventie medicala. Revista si site-ul au un continut bogat de articole si informatii cu adresabilitate catre publicul larg.\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/jurmed.ro\/pacienti\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"ro-RO\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/jurmed.ro\/pacienti\/#\/schema\/person\/33a8cfa97687970b1e60b21cfefad2fa\",\"name\":\"Gabriel\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"ro-RO\",\"@id\":\"https:\/\/jurmed.ro\/pacienti\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/accc2b7d0bf4c444234bb0c0aeb071080c96c00f426597754320e627a9d759fb?s=96&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/accc2b7d0bf4c444234bb0c0aeb071080c96c00f426597754320e627a9d759fb?s=96&r=g\",\"caption\":\"Gabriel\"},\"url\":\"https:\/\/jurmed.ro\/pacienti\/author\/gabrielb\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Progres major \u00een managementul cancerului de prostat\u0103: Darolutamida devine disponibil\u0103 pacien\u021bilor din Rom\u00e2nia \u00eencep\u00e2nd cu 2026 - Jurmed - Pacienti","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/jurmed.ro\/pacienti\/progres-major-in-managementul-cancerului-de-prostata-darolutamida-devine-disponibila-pacientilor-din-romania-incepand-cu-2026\/","og_locale":"ro_RO","og_type":"article","og_title":"Progres major \u00een managementul cancerului de prostat\u0103: Darolutamida devine disponibil\u0103 pacien\u021bilor din Rom\u00e2nia \u00eencep\u00e2nd cu 2026 - Jurmed - Pacienti","og_description":"&nbsp; Pacien\u021bii din Rom\u00e2nia care sufer\u0103 de cancer de prostat\u0103 beneficiaz\u0103, \u00eencep\u00e2nd cu acest an, de o nou\u0103 op\u021biune terapeutic\u0103 esen\u021bial\u0103. Bayer anun\u021b\u0103 disponibilitatea darolutamidei pe pia\u021ba local\u0103, un inhibitor [&hellip;]","og_url":"https:\/\/jurmed.ro\/pacienti\/progres-major-in-managementul-cancerului-de-prostata-darolutamida-devine-disponibila-pacientilor-din-romania-incepand-cu-2026\/","og_site_name":"Jurmed - Pacienti","article_published_time":"2026-04-02T10:02:29+00:00","og_image":[{"width":600,"height":324,"url":"https:\/\/jurmed.ro\/pacienti\/wp-content\/uploads\/sites\/3\/2026\/04\/Medinst_Logo___1_300_162_r@2x.jpg","type":"image\/jpeg"}],"author":"Gabriel","twitter_misc":{"Scris de":"Gabriel","Timp estimat pentru citire":"4 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/jurmed.ro\/pacienti\/progres-major-in-managementul-cancerului-de-prostata-darolutamida-devine-disponibila-pacientilor-din-romania-incepand-cu-2026\/#article","isPartOf":{"@id":"https:\/\/jurmed.ro\/pacienti\/progres-major-in-managementul-cancerului-de-prostata-darolutamida-devine-disponibila-pacientilor-din-romania-incepand-cu-2026\/"},"author":{"name":"Gabriel","@id":"https:\/\/jurmed.ro\/pacienti\/#\/schema\/person\/33a8cfa97687970b1e60b21cfefad2fa"},"headline":"Progres major \u00een managementul cancerului de prostat\u0103: Darolutamida devine disponibil\u0103 pacien\u021bilor din Rom\u00e2nia \u00eencep\u00e2nd cu 2026","datePublished":"2026-04-02T10:02:29+00:00","mainEntityOfPage":{"@id":"https:\/\/jurmed.ro\/pacienti\/progres-major-in-managementul-cancerului-de-prostata-darolutamida-devine-disponibila-pacientilor-din-romania-incepand-cu-2026\/"},"wordCount":813,"commentCount":0,"image":{"@id":"https:\/\/jurmed.ro\/pacienti\/progres-major-in-managementul-cancerului-de-prostata-darolutamida-devine-disponibila-pacientilor-din-romania-incepand-cu-2026\/#primaryimage"},"thumbnailUrl":"https:\/\/jurmed.ro\/pacienti\/wp-content\/uploads\/sites\/3\/2026\/04\/Medinst_Logo___1_300_162_r@2x.jpg","keywords":["oncologie","Progres major \u00een managementul cancerului de prostat\u0103: Darolutamida devine disponibil\u0103 pacien\u021bilor din Rom\u00e2nia \u00eencep\u00e2nd cu 20"],"articleSection":["Articole"],"inLanguage":"ro-RO","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/jurmed.ro\/pacienti\/progres-major-in-managementul-cancerului-de-prostata-darolutamida-devine-disponibila-pacientilor-din-romania-incepand-cu-2026\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/jurmed.ro\/pacienti\/progres-major-in-managementul-cancerului-de-prostata-darolutamida-devine-disponibila-pacientilor-din-romania-incepand-cu-2026\/","url":"https:\/\/jurmed.ro\/pacienti\/progres-major-in-managementul-cancerului-de-prostata-darolutamida-devine-disponibila-pacientilor-din-romania-incepand-cu-2026\/","name":"Progres major \u00een managementul cancerului de prostat\u0103: Darolutamida devine disponibil\u0103 pacien\u021bilor din Rom\u00e2nia \u00eencep\u00e2nd cu 2026 - Jurmed - Pacienti","isPartOf":{"@id":"https:\/\/jurmed.ro\/pacienti\/#website"},"primaryImageOfPage":{"@id":"https:\/\/jurmed.ro\/pacienti\/progres-major-in-managementul-cancerului-de-prostata-darolutamida-devine-disponibila-pacientilor-din-romania-incepand-cu-2026\/#primaryimage"},"image":{"@id":"https:\/\/jurmed.ro\/pacienti\/progres-major-in-managementul-cancerului-de-prostata-darolutamida-devine-disponibila-pacientilor-din-romania-incepand-cu-2026\/#primaryimage"},"thumbnailUrl":"https:\/\/jurmed.ro\/pacienti\/wp-content\/uploads\/sites\/3\/2026\/04\/Medinst_Logo___1_300_162_r@2x.jpg","datePublished":"2026-04-02T10:02:29+00:00","author":{"@id":"https:\/\/jurmed.ro\/pacienti\/#\/schema\/person\/33a8cfa97687970b1e60b21cfefad2fa"},"breadcrumb":{"@id":"https:\/\/jurmed.ro\/pacienti\/progres-major-in-managementul-cancerului-de-prostata-darolutamida-devine-disponibila-pacientilor-din-romania-incepand-cu-2026\/#breadcrumb"},"inLanguage":"ro-RO","potentialAction":[{"@type":"ReadAction","target":["https:\/\/jurmed.ro\/pacienti\/progres-major-in-managementul-cancerului-de-prostata-darolutamida-devine-disponibila-pacientilor-din-romania-incepand-cu-2026\/"]}]},{"@type":"ImageObject","inLanguage":"ro-RO","@id":"https:\/\/jurmed.ro\/pacienti\/progres-major-in-managementul-cancerului-de-prostata-darolutamida-devine-disponibila-pacientilor-din-romania-incepand-cu-2026\/#primaryimage","url":"https:\/\/jurmed.ro\/pacienti\/wp-content\/uploads\/sites\/3\/2026\/04\/Medinst_Logo___1_300_162_r@2x.jpg","contentUrl":"https:\/\/jurmed.ro\/pacienti\/wp-content\/uploads\/sites\/3\/2026\/04\/Medinst_Logo___1_300_162_r@2x.jpg","width":600,"height":324},{"@type":"BreadcrumbList","@id":"https:\/\/jurmed.ro\/pacienti\/progres-major-in-managementul-cancerului-de-prostata-darolutamida-devine-disponibila-pacientilor-din-romania-incepand-cu-2026\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/jurmed.ro\/pacienti\/"},{"@type":"ListItem","position":2,"name":"Progres major \u00een managementul cancerului de prostat\u0103: Darolutamida devine disponibil\u0103 pacien\u021bilor din Rom\u00e2nia \u00eencep\u00e2nd cu 2026"}]},{"@type":"WebSite","@id":"https:\/\/jurmed.ro\/pacienti\/#website","url":"https:\/\/jurmed.ro\/pacienti\/","name":"Jurmed - Pacienti","description":"JURMED \u2013 Jurnal de Sanatate este o publicatie lunara de informare si preventie medicala. Revista si site-ul au un continut bogat de articole si informatii cu adresabilitate catre publicul larg.","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/jurmed.ro\/pacienti\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"ro-RO"},{"@type":"Person","@id":"https:\/\/jurmed.ro\/pacienti\/#\/schema\/person\/33a8cfa97687970b1e60b21cfefad2fa","name":"Gabriel","image":{"@type":"ImageObject","inLanguage":"ro-RO","@id":"https:\/\/jurmed.ro\/pacienti\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/accc2b7d0bf4c444234bb0c0aeb071080c96c00f426597754320e627a9d759fb?s=96&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/accc2b7d0bf4c444234bb0c0aeb071080c96c00f426597754320e627a9d759fb?s=96&r=g","caption":"Gabriel"},"url":"https:\/\/jurmed.ro\/pacienti\/author\/gabrielb\/"}]}},"_links":{"self":[{"href":"https:\/\/jurmed.ro\/pacienti\/wp-json\/wp\/v2\/posts\/10516","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/jurmed.ro\/pacienti\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/jurmed.ro\/pacienti\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/jurmed.ro\/pacienti\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/jurmed.ro\/pacienti\/wp-json\/wp\/v2\/comments?post=10516"}],"version-history":[{"count":1,"href":"https:\/\/jurmed.ro\/pacienti\/wp-json\/wp\/v2\/posts\/10516\/revisions"}],"predecessor-version":[{"id":10518,"href":"https:\/\/jurmed.ro\/pacienti\/wp-json\/wp\/v2\/posts\/10516\/revisions\/10518"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/jurmed.ro\/pacienti\/wp-json\/wp\/v2\/media\/10517"}],"wp:attachment":[{"href":"https:\/\/jurmed.ro\/pacienti\/wp-json\/wp\/v2\/media?parent=10516"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/jurmed.ro\/pacienti\/wp-json\/wp\/v2\/categories?post=10516"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/jurmed.ro\/pacienti\/wp-json\/wp\/v2\/tags?post=10516"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}